Which one is better, Panitumumab or Bevacizumab?

Panitumumab (Panitumumab) is an immunoglobulin G monoclonal antibody against epidermal growth factor receptor (EGFR), while bevacizumab is a targeting monoclonal antibody against vascular endothelial growth factor (VEGF). Compared with chemotherapy alone, the combination therapy of chemotherapy plus bevacizumab (C+B) has been proven to improve prognosis and is an option for first-line treatment of metastatic colorectal cancer (mCRC); the combination therapy of chemotherapy plus panitumumab (C+P) has been proven to be better than chemotherapy alone. Compared with C+B, adding anti-EGFR to chemotherapy significantly improved OS; there was more heterogeneity due to anti-EGFR drugs including panitumumab and cetuximab. In contrast, two trials reported no significant improvements in OS and progression-free survival between C+P and C+B.